Curio Bioscience v 10x Genomics (CoA, 17 December 2024)
| Date | 17 December 2024 |
|---|---|
| Court | CoA |
| Division | Luxembourg (LU) |
| Type of action | Application Rop 223 |
| Registry reference | App_66516/2024 · ORD_66752/2024 |
| Parties | Curio Bioscience, Inc v. 10x Genomics, Inc. |
Official decision (PDF) · UPC registry entry
Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.
Dhenne Avocats · 10 October 2026
Our analysis
Summary
In an order of 17 December 2024 (UPC_CoA_810/2024), the standing judge of the Court of Appeal rejected Curio Bioscience’s application for suspensive effect against the Düsseldorf Local Division’s order of 3 December 2024, which required it to provide security of €200,000 for 10x Genomics’ legal costs within four weeks (EP 2 697 391). The order confirms that suspensive effect remains exceptional, all the more so in an appeal against a procedural order, and that extreme urgency must be established by the applicant, separately from any claim that the impugned order is manifestly wrong.
Question
Do extreme urgency and exceptional circumstances justify suspending an order for security for costs pending an appeal brought under Rule 220.2?
Decision
The standing judge may reject the application without hearing the respondent (paragraph 6). Suspensive effect is granted only in exceptional circumstances, particularly where the impugned order falls under Rule 220.2 (paragraph 8). Curio did not establish extreme urgency: it merely argued that it would have to comply with a manifestly wrong order or risk a default decision (paragraphs 9 and 10). Whether an order is manifestly wrong is a test distinct from urgency. In the light of Rule 158 the order did not appear manifestly wrong, its interplay with Article 69(4) UPCA being a matter for the appeal on the merits (paragraph 11). Curio’s interests did not outweigh those of 10x Genomics and the requirements of due process (paragraph 12).
Key points for practice
- An application for suspensive effect made on grounds of extreme urgency must prove that urgency with its own evidence, separate from criticism of the impugned order.
- The risk of a default decision for failure to provide security does not in itself amount to exceptional circumstances.
Provisions applied
- Agreement on a Unified Patent Court
- Arts 41(1), 69(4) and 74(1)
- Rules of Procedure
- Rules 158, 220.2 and 223
- Case law cited
- ICPillar v ARM, Court of Appeal, 19 June 2024
Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.
Going further
Lexicon: UPC Court of Appeal.
Dhenne Avocats blog: UPC Appeals: What the Numbers Show.
Source and translations
- Official source
- Unified Patent Court registry link recorded in the record
- Original language
- not recorded
- Translation available
- no translation recorded the firm’s French record is a summary, not a translation
- Date checked
- not recorded
Follow this case
Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.
Proceedings
Parties
- defendant10x Genomics, Inc.57 decisions in the corpusFollow this party
- claimantCurio Bioscience, Inc.29 decisions in the corpusFollow this party
Decisions in the same proceedings and documented appeals
What the record states
- Nature of the act
- Application Rop 223
- Outcome (Dhenne Avocats summary)
- La demande d’effet suspensif contre l’ordonnance imposant une garantie pour frais de 200 000 euros est rejetée, faute d’extrême urgence démontrée et de circonstances exceptionnelles.
- Appeal
- Decision of the Court of Appeal.
- Instance
- Court of Appeal decision.
Patents mentioned
EP 2 697 391mentioned in: Dhenne Avocats analysis Follow this patent
Related decisions cited in the analyses
- ICPillar v ARM (CoA, 19 June 2024) cited in this record
Patents and standards
| Publication | Role in the dispute | Family | Standard and declaration | Pool | Sources |
|---|---|---|---|---|---|
EP 2 697 391Method and product for localised or spatial detection of nucleic acid in a tissue sample recorded proprietor: Spatial Transcriptomics AB | Mentioned in the analysis (role not qualified) Also mentioned in 28 other decision(s): 10x Genomics v Curio Bioscience (CFI, ORD_598272/2023, 30 April 2024) · 10x Genomics v Curio Bioscience (CFI, UPC_CFI_658/2025, 2 February 202 · 10x Genomics v Curio Bioscience (CFI, UPC_CFI_657/2025, 2 February 202 · 10x Genomics v Curio Bioscience (CFI, 5 August 2025) · 10x Genomics v Curio Bioscience (CFI, 4 August 2025) · 10x Genomics v Curio Bioscience (CFI, 16 June 2025) · 10x Genomics v Curio Bioscience (CFI, 4 June 2025) · 10x Genomics v Curio Bioscience (CFI, 2 May 2025) | not recorded | not recorded | not recorded | Espacenet · European Patent Register existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically) mentioned in: Dhenne Avocats analysis |
Receive an alert
Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.